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Abstract
Hypothesis/introduction
The risks and benefits of angiotensin-converting
enzyme (ACE) inhibitors in patients with end-stage
renal disease (ESRD) after cardiac events are
unknown. We sought to determine the independent
effect of ACE inhibitors (ACE-I) on long-term
mortality in ESRD patients after cardiac events.
Materials and methods
We analysed a prospective coronary care unit registry
and identified 527 ESRD patients, 368 with complete
data on medications prescribed, over eight years at a
single, tertiary centre.
Results
The overall mean age was 64.4+13.8 years with 54.9%
men, and 59.2% African-American. A total of
143/386 (37.0%) were prescribed ACE-I during the
hospital stay for cardiac reasons, including congestive
heart failure (CHF) 52.8% and acute coronary
syndromes (ACS) 47.2%. There were no significant
differences in the rates of hypotension or arrhythmias
in those who were treated with ACE-I versus those
who were not. Survival analysis over three years,
adjusted for known confounders, demonstrated a
37% reduction in all-cause mortality in those who
received ACE-I, (p=0.0145).
Conclusions
In the setting of coronary care unit admission for
CHF and ACS, ESRD patients selected for ACE-I,
did not have increased rates of adverse haemodynamic
or arrhythmic complications. The use of ACE-I
conferred an independent mortality reduction over
long-term follow-up.
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Introduction
We and others have demonstrated that chronic
kidney disease (CKD) including end-stage renal
disease (ESRD) requiring renal-replacement
therapy are independent risk factors for morbidity
and mortality after a variety of cardiac events.1-4
ESRD carries the highest risk of coronary heart
disease death of any acquired medical condition.2
Because CKD patients have been excluded from
randomised trials of cardioprotective therapy, little
is known about their risks and benefits in CKD,
and in particular, in ESRD.5 We sought to evaluate
the short-term risks and benefits of angiotensinconverting enzyme (ACE) inhibitors in ESRD, given

to patients in the coronary care unit after cardiac
events.
Methods
Setting, data collection and follow-up
Henry Ford Hospital is a 903-bed tertiary care
centre, located in the urban core of the Detroit
metropolitan area, and receives patients whose
care is provided primarily within the Henry Ford
Health System, a vertically integrated, mixedmodel managed care organisation with an
advanced information technology infrastructure.6-8
The Henry Ford Hospital Cardiac Intensive Care
Unit Database characteristics have been published
elsewhere.1 Briefly, this was a registry in which
every admission to this 16-bed unit had clinical
data (~250 discrete elements) prospectively
recorded on case report forms by trained research
assistants. Data collected from 5/1/1990 to
8/22/1998 included baseline demographics, laboratory values, and events occurring during the
unit stay, such as revascularisation and complications. The data collection period was stopped
after discharge from the unit, either to another
floor or to home. Mortality during the cardiac
intensive care unit stay was recorded prospectively. Vital status was tracked on an annual basis
using a multilayered approach. This approach
called for ascertainment of future activity in the
health system by the patient, confirmation of
death by identification matching with the State of
Michigan Death Certificate Registry, or record of a
death on a later hospitalisation within the health
system. Finally, for those not identified with any of
the above means, the National Death Index was
used to confirm death primarily in a state other
than Michigan. These strategies yielded a 99%
overall vital status ascertainment rate for patients
followed after the first cardiac intensive care unit
admission longitudinally over a mean of 36
months (minimum 0, maximum 100).
Outcome validation
Arrhythmic, haemodynamic, and fatal outcomes
were selected for validation with blinded chart
abstraction. A random sample, n=20, from each
outcome category was chosen and each record
was compared against chart abstraction for the
development of the outcome during the coronary
care unit stay. Agreement statistics were computed for each outcome and then averaged over the
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Table 1 Baseline characteristics of ESRD patients admitted to a coronary care unit treated with or without ACE-I.
Characteristic

Age
Male
Female
African-American
Caucasian
Other race
Hypertension
Diabetes
Smoking
Prior cardiac revascularisation
History of CHF

Chronic medications
ACE-I
Beta-blocker
Discharge diagnoses
UA/NSTEMI
STEMI
CHF

ACE-I
(n=143)

No ACE-I
(n=225)

p-value

64.0+14.3
75 (52.4)
68 (47.6)
81 (56.6)
57 (39.9)
5 (3.5)
122 (85.3)
76 (53.1)
76 (53.1)
34 (23.8)

65.4+13.0
137 (60.9)
88 (39.1)
137 (60.9)
82 (36.4)
6 (2.7)
179 (79.6)
123 (54.7)
91 (40.4)
30 (13.3)

0.34
0.11
0.11
0.41
0.51
0.89
0.16
0.78
0.02
0.01

94 (65.7)

89 (39.6)

<0.0001

86 (62.8)
24 (18.8)

38 (17.6)
33 (15.2)

<0.0001
0.39

29 (20.3)
15 (10.5)
99 (69.2)

103 (45.7)
17 (7.6)
105 (46.7)

<0.0001
0.33
<0.0001

ACE-I = angiotensin-converting enzyme inhibitor, UA/NSTEMI = unstable angina/non-ST-elevation myocardial infarction, STEMI = ST-elevation
myocardial infarction, CHF = congestive heart failure.

Table 2 In-hospital complications according to ACE-I use. Hypotension = sustained systolic blood pressure <90 mmHg
with signs of hypoperfusion, hypertension = sustained systolic blood pressure >180 mmHg.
Complication

ACE-I
(n=143)

(Including other
peptidergic systems)

September 2002
Volume 3
Number 3

p-value

Hypotension

31 (21.7)

54 (24.0)

0.61

Hypertension

41 (28.7)

42 (18.7)

0.03

Atrial fibrillation/flutter

23 (16.1)

41 (18.2)

0.60

Ventricular tachycardia

5 (3.5)

14 (6.2)

0.24

Ventricular fibrillation

8 (5.6)

7 (3.1)

0.24

In-hospital death

6 (4.2)

12 (5.3)

0.62

12 categories. The mean percent agreement was
92.7% across the eleven outcomes.

Journal of
the ReninAngiotensinAldosterone
System

No ACE-I
(n=225)

Statistical analysis
Baseline characteristics are reported with
means+standard deviation (SD) or proportions
with 95% confidence intervals (CI), as appropriate, with exclusion of missing data points.
Univariate comparisons were carried out using
analysis of variance, or Chi-square as appropriate.
Cox proportional hazards model was used to
derive the independent predictors of time to
cumulative death as the primary outcome. All
models were tested for interactions and none
were found. The log-rank test was used to evaluate the independent differences in survival across
the strata. All p-values are two-tailed and considered significant at α <0.05.

of ACE-I are given in Table 1. A total of 143/386
(37.0%) were prescribed ACE-I during the hospital
stay for cardiac reasons, including congestive
heart failure (CHF) 52.8% and acute coronary syndromes (ACS) 47.2%. More patients in the ACE-I
group were receiving ACE-I prior to their hospital
admission. Also, the majority (69.2%) of patients
who received ACE-I were admitted for CHF.
Overall, 54.1% had a history of diabetes, and presumably, had diabetic nephropathy as the aetiology of ESRD. The duration on dialysis was not
recorded on the case report form. The admission
serum potassium level was 4.5+1.0 and 4.7+1.1
mmol/L for those treated with and without ACE-I,
respectively, (p=0.14). The admission haemoglobin was 11.3+2.2 and 10.1+2.5 g/dl for those
treated with and without ACE-I, respectively,
p<0.0001.

Results
Baseline characteristics
The overall mean age was 64.4+13.8, range 20 to
93 years. Baseline characteristics according to use

In-hospital complications
In-hospital complications are given in Table 2.
There were no differences in the rates of hypotension or arrhythmias. Hypotension was defined as
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Figure 1 Long-term survival in 368 patients with ESRD
treated with angiotensin-converting enzyme inhibitor
(ACE-I) after a cardiac event.
1.0
p=0.0145
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a sustained systolic blood pressure <90 mmHg,
with signs of hypoperfusion. The development of
hypertension was more common among those
treated with ACE-I and may reflect an indication
for ACE-I treatment. The complications of
angioedema, cough, and hyperkalaemia were not
recorded on the case report form. There was no
difference between the rates of in-hospital mortality, 4.2% vs. 5.3%, p=0.62, for those prescribed
ACE-I versus not.
Long-term survival
Figure 1 displays survival over long-term followup. The mean and median survival was 43.2+3.3
and 30.0+3.9, and 32.4+2.3 and 19.5+3.5 months
for those treated with and without ACE-I, respectively. Cox proportional hazards regression
revealed the independent reduction in the hazard
for death for ACE-I was RR=0.63, 95% CI
0.47–0.83, p=0.001. A history of CHF was found
to be a significant adverse predictor of death,
RR=1.52, 95% CI 1.16–1.99, p=0.002. Factors not
found to be significant in the model included age,
sex, race, β-blocker use, and diabetes. When the
model was restricted to either ACS patients alone
or CHF patients alone, the overall relative risk
reduction for ACE-I remained the same. However,
all variables in the model became insignificant due
to a lack of stability from too few endpoints.
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Discussion
Our study has demonstrated an independent, 37%
reduction in all-cause mortality after hospitalisation for cardiac events, primarily ACS and CHF,
with the use of ACE-I. Although the overall survival with ESRD patients after cardiac events was
poor, the relative risk reduction observed with
ACE-I is on par with the 20–40% reduction in
death seen in the general population in the treatment of acute myocardial infarction (MI) and CHF.9
Although we did not record additional events, we
would expect that rates of recurrent MI, hospitalisation for CHF, and sudden death would also be
reduced with ACE-I.9

Robson originally reported the first clinical
trial of ACE-I in ESRD in a 107-patient randomised,
factorial design.10 This trial evaluated cerivastatin
(10 mg per day) and enalapril (2.5–5 mg per day)
in ESRD patients on haemo- or peritoneal dialysis.
The enalapril arm of this trial was stopped early
because of an excessive incidence of hypotension.
In a recent prospective study of 11 ESRD patients,
Agarwal and co-workers demonstrated that lisinopril, 40 mg once a day, three times a week, can be
used safely in ESRD with considerable reductions
in systolic and diastolic blood pressure, 22 and 11
mmHg, respectively.11 We observed that patients
in our study, if anything, tended to be hypertensive
during their stay, and it is quite possible that the
ACE-I was used in addition to other drugs with the
primary intent of controlling hypertension.
One of the benefits of ACE-I in ESRD is a predictable reduction in left ventricular (LV) mass
index. Regression of LV hypertrophy is a leading
mechanism by which ACE-I modify the natural
history of cardiac disease, in particular CHF and
sudden death.12 Dyadyk and co-workers demonstrated a 20% reduction in LV mass index over 12
months in ESRD patients treated with either captopril or enalapril.13 There have been no clinical
trials of treatment for ACS or CHF in patients with
ESRD. We have recently shown that CKD patients,
including ESRD, in the setting of ST-segment elevation MI (STEMI), significantly benefit from the
use of aspirin and β-blockers.14 Our data from the
present study, confirm that ACE-I are cardioprotective for ESRD patients across a variety of cardiac
events, including ACS (with a small subgroup of
STEMI) and CHF. Although these analyses cannot
stand in the place of clinical trials, they do suggest
that those patients selected for these therapies,
whether due to the effect of the drug, or to the
characteristics of the patients, have improved survival over those not prescribed these agents.
One of the concerns regarding the use of ACEI in ESRD is the worsening of anaemia related to
erythropoietin deficiency.15-16 However, in a recent
crossover trial of 51 patients with ESRD, ACE-I
were not shown to be related to the level of
haemoglobin or to the need for increasing erythropoietin dosage.17 Our study was not designed
to address this issue; however, we did note that
those selected for ACE-I had higher haemoglobin
levels than those not selected for ACE-I. While the
ACE-I-erythropoietin interaction remains controversial, it is prudent to closely monitor the haemoglobin level and to adjust erythropoietin doses
accordingly if ACE-I are going to be used in ESRD.
Study limitations
Our study has many of the limitations that are
common to retrospective analyses of prospectively collected data. First and most importantly, we
could not control for selection bias. That is, clinicians chose to use ACE-I based on clinical scenarios and perceived benefit to the patient. The most
common condition driving the choice of ACE-I
was CHF. However, we controlled for CHF in the
multivariate modelling and found ACE-I to have
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conferred benefit. Unfortunately we did not have
the specific ACE-I or dosage used. This is important, due to the different rates of renal clearance
within the ACE-I class.18 Also very importantly, we
did not have medication use data collected over
the long term, and made the assumption that the
in-hospital course of therapy set the outpatient
management programme. Lack of adherence to
ACE-I, or changes to other non-ACE-I drugs by outpatient physicians, would have if anything, caused
bias to the null hypothesis. Lastly, we did not track
ACE-I specific adverse events in the case report
form, such as angioedema, cough, and the development of hyperkalaemia. These events almost
certainly dictated, in some cases, who received an
ACE-I and who did not.
Although heavily confounded and influenced
by selection bias, our data suggest that those individuals with ESRD selected for ACE-I on admission
for cardiac events have considerable opportunity
for cardioprotection. The survival benefit we
observed should be validated in two prospective,
double-blind randomised trials, one in ACS and one
in CHF. Such trials should carefully assess for
adverse events, including hypotension, angioedema, cough and, importantly, hyperkalaemia – all of
which we could not completely account for in our
data. It is only through a clinical trials programme
in ESRD that inroads will be made with this subgroup, which has the highest cardiac death rate
recognised today.19
Conclusions
We observed that ACE-I were used in 39% of ESRD
patients admitted to a coronary care unit primarily for ACS and CHF. For those patients selected for
ACE-I, there were no adverse haemodynamic or
arrhythmic complications. The use of ACE-I conferred an independent, 37% mortality reduction
over long-term follow-up.
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